The company states: “Commercial revenue for the full year 2023 is expected to be in the range of $51 to $53 million, reflecting a lower bound of 50% and upper bound of 56% growth over the same period in the prior year. Gross margin for the full year 2023 expected to be in the range of 83% to 85%.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RCEL:
- Avita Medical reports Q3 EPS (34c), consensus (44c)
- AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
- AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
- Avita Medical announces distribution partnership with PolyMedics
- Avita Medical Ltd (RCEL) Q3 Earnings Cheat Sheet